Skip to main content
IRWD logo

IRWD · Ironwood Pharmaceuticals Inc · Investor Relations

Track IRWD — free
$4.67 -0.12 (-2.41%) Play latest call Q3 2026 earnings call transcript
Market Cap
$767.33M
Shares
165.55M
Volume · Nov 19 948.72K Avg daily vol (3M) 2.1M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-05 Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance
2026-10-28 Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
2026-10-16 Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
2026-09-03 Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
2026-08-06 Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
2026-07-30 Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
2026-07-14 Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
2026-05-28 Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
2026-05-27 FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
2026-05-07 Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
2026-05-04 Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
2026-04-30 Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
2026-04-23 Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
2026-03-04 Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
2026-02-25 Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
2026-02-18 Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
2026-01-02 Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
2025-11-10 Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
2025-08-07 Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
2025-05-07 Ironwood Pharmaceuticals Reports First Quarter 2025 Results
2025-04-30 Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
2025-04-25 Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
2025-04-22 Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
2025-04-14 Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
2025-03-27 Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Past events

Date Event Type
2026-11-05 Ironwood Pharmaceuticals Q3 2026 Investor Update Conference Call Earnings call
2026-09-10 Wells Fargo 21st Annual Healthcare Conference Conference
2026-08-06 Ironwood Pharmaceuticals Q2 2026 Investor Update Conference Call Earnings call
2026-06-04 Jefferies Global Healthcare Conference Conference
2026-05-07 Ironwood Pharmaceuticals Q1 2026 Investor Update Conference Call Earnings call
2026-03-11 The Citizens Life Sciences Conference Conference
2026-02-25 Ironwood Pharmaceuticals Q4 and Full Year 2025 Investor Update Conference Call Earnings call
2025-05-07 The Citizens Life Sciences Conference Conference
2025-02-27 Ironwood Pharmaceuticals Q4 and Full Year 2024 Investor Update Conference Call Earnings call
2025-01-29 Ironwood Pharmaceuticals Corporate Update Event
2024-12-04 Piper Sandler 36th Annual Healthcare Conference Conference
2024-11-20 Jefferies London Healthcare Conference Conference
2024-11-07 Ironwood Pharmaceuticals Q3 2024 Investor Update Conference Call Earnings call
2024-10-29 ACG Oral Presentation of STARS Subgroup Analyses by Baseline Demographics and SBS Disease Characteristics Presentation
2024-09-05 2024 Wells Fargo Healthcare Conference Conference
2024-08-08 Ironwood Pharmaceuticals Q2 2024 Investor Update Conference Call Earnings call
2024-06-06 Jefferies Global Healthcare Conference Conference
2024-05-21 Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Presentation
2024-05-13 The Citizens JMP Life Sciences Conference Conference
2024-05-09 Ironwood Pharmaceuticals Q1 2024 Investor Update Conference Call Earnings call
2024-02-29 STARS Phase 3 Positive Topline Results Conference Call Earnings call
2024-02-15 Ironwood Pharmaceuticals Q4 and Full Year 2023 Investor Update Conference Call Earnings call
2024-01-10 42nd Annual J.P. Morgan Healthcare Conference Conference
2023-11-29 Piper Sandler 35th Annual Healthcare Conference Conference
2023-11-09 Ironwood Pharmaceuticals Q3 2023 Investor Update Conference Call Earnings call

Source: https://investor.ironwoodpharma.com/home/default.aspx

Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 243 filings 221 filers Visit website Investor relations